Skip to main content

Advertisement

SpringerLink
Log in

A single-loop recombinant pseudotyped-virus-based assay to detect HIV-1 phenotypic resistance

  • Original Article
  • Published:
Archives of Virology Aims and scope Submit manuscript

Abstract

HIV/AIDS is a leading public health concern throughout the world. Currently, treatment of HIV/AIDS still depends on highly active antiretroviral therapy (HAART); however, there is increasing evidence showing the emergence of resistance to antiretroviral drugs in HIV-1 strains, making ART less effective over time. Intensive monitoring of HIV-1 drug resistance is therefore of great importance to evaluate the current sensitivity of antiretroviral agents and is urgently needed. The aim of this study was to develop a single-loop recombinant pseudotyped-virus-based assay to detect phenotypic resistance in clinical HIV-1 strains. HIV-1 RNA was extracted from HIV-1-infected human plasma samples, and an approximately 3-kb fragment containing p7/p1/p6 cleavage sites and full-length protease (PR), reverse transcriptase (RT), thermonuclease (TNase), and integrase (1–280 aa) genes was amplified by nested RT-PCR. A retroviral vector was constructed using the HIV-1 infectious molecular clone pLWJ to test antiretroviral drug susceptibility. pLWJ-SV40-Luc contained a luciferase expression cassette inserted within a deleted region of the envelope (env) gene as an indicator gene. Resistance test vectors (RTVs) were constructed by incorporating amplified target genes into pLWJ-SV40-Luc by using ApaI or AgeI and AarI restriction sites and conventional cloning methods. The virus stocks used for drug susceptibility test were produced by co-transfecting 293T cells with RTVs and a plasmid that provided vesicular stomatitis virus glycoprotein (VSV-G). Viral replication was monitored by measuring luciferase activity in infected target cells at approximately 48 h postinfection. A total of 35 clinical plasma samples from HIV-1-infected humans were tested, and target fragments were successfully amplified from 34 samples (97.1 %) and 33 RTVs were successfully constructed by directional cloning, with an overall success rate of 94.3 %. A clear-cut dose-dependent relationship was detected between virus production and luciferase activity in the constructed phenotypic resistance testing system. The highest coefficient of determination (R 2) was found between luciferase activity and drug concentration and viral inhibition at 293T cell concentrations of 5 × 104 cells per well. The phenotypic profiles of the viruses from 29 clinical samples almost completely matched the observed genotypes. The results demonstrate that a single-loop recombinant pseudotyped-virus-based assay was successfully developed, and this testing system has high stability and appears to be applicable for testing phenotypic resistance of clinical HIV-1 strains to commonly used antiretroviral agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Zhang KL, Detels R, Liao S, Cohen M, Yu DB (2008) China’s HIV/AIDS epidemic: continuing challenges. Lancet 372:1791–1793

    Article  PubMed  Google Scholar 

  2. Zheng H, Wang L, Huang P, Norris J, Wang Q, Peng Z, Yu R, Wang N (2014) Incidence and risk factors for AIDS-related mortality in HIV patients in China: a cross-sectional study. BMC Public Health 14:831

    Article  PubMed Central  PubMed  Google Scholar 

  3. Jiang ZS, Jiang JN (2012) Research progress in death risk factors of HIV infector and AIDS patients. Inter J Epidemiol Infect Dis 39:63–67

    Google Scholar 

  4. Jin Y, Liu Z, Wang X, Liu H, Ding G, Su Y, Zhu L, Wang N (2014) A systematic review of cohort studies of the quality of life in HIV/AIDS patients after antiretroviral therapy. Int J STD AIDS (in press)

  5. Piacenti FJ (2006) An update and review of antiretroviral therapy. Pharmacotherapy 26:1111–1133

    Article  CAS  PubMed  Google Scholar 

  6. Brechtl JR, Breitbart W, Galietta M, Krivo S, Rosenfeld B (2001) The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: impact on medical, palliative care, and quality of life outcomes. J Pain Symptom Manag 21:41–51

    Article  CAS  Google Scholar 

  7. Maltêz F, Doroana M, Branco T, Valente C (2001) Recent advances in antiretroviral treatment and prevention in HIV-infected patients. Curr Opin HIV AIDS 6:S21–S30

    Article  Google Scholar 

  8. Burgoyne RW, Tan DH (2008) Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act. J Antimicrob Chemother 61:469–473

    Article  CAS  PubMed  Google Scholar 

  9. Granich R, Crowley S, Vitoria M, Smyth C, Kahn JG, Bennett R, Lo YR, Souteyrand Y, Williams B (2010) Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. Curr Opin HIV AIDS 5:298–304

    Article  PubMed Central  PubMed  Google Scholar 

  10. Granich R, Crowley S, Vitoria M, Lo YR, Souteyrand Y, Dye C, Gilks C, Guerma T, De Cock KM, Williams B (2010) Highly active antiretroviral treatment for the prevention of HIV transmission. J Int AIDS Soc 13:1

    Article  PubMed Central  PubMed  Google Scholar 

  11. Auvert B, Males S, Puren A, Taljaard D, Caraël M, Williams B (2004) Can highly active antiretroviral therapy reduce the spread of HIV?: A study in a township of South Africa. J Acquir Immune Defic Syndr 36:613–621

    Article  PubMed  Google Scholar 

  12. Gupta R, Hill A, Sawyer AW, Pillay D (2008) Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 47:712–722

    Article  PubMed  Google Scholar 

  13. Shafer RW, Schapiro JM (2008) HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 10:67–84

    PubMed Central  PubMed  Google Scholar 

  14. Little SJ, Daar ES, D’Aquila RT, Keiser PH, Connick E, Whitcomb JM, Hellmann NS, Petropoulos CJ, Sutton L, Pitt JA, Rosenberg ES, Koup RA, Walker BD, Richman DD (1999) Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282:1142–1149

    Article  CAS  PubMed  Google Scholar 

  15. Clavel F, Hance AJ (2004) HIV drug resistance. N Engl J Med 350:1023–1035

    Article  CAS  PubMed  Google Scholar 

  16. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA (2000) Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 283:381–390

    Article  CAS  PubMed  Google Scholar 

  17. Hirsch HH, Drechsler H, Holbro A, Hamy F, Sendi P, Petrovic K, Klimkait T, Battegay M (2005) Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care. Eur J Clin Microbiol Infect Dis 24:733–738

    Article  CAS  PubMed  Google Scholar 

  18. MacArthur RD (2009) Understanding HIV phenotypic resistance testing: usefulness in managing treatment-experienced patients. AIDS Rev 11:223–230

    PubMed  Google Scholar 

  19. Qari SH, Respess R, Weinstock H, Beltrami EM, Hertogs K, Larder BA, Petropoulos CJ, Hellmann N, Heneine W (2002) Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. J Clin Microbiol 40:31–35

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Wu SL, Yan YS, Yan PP, Huang HL, Wang HR (2010) Construction and characterization of a full-length infectious clone from a fast-replicating, X4-tropic HIV-1 subtype B’ isolate. Arch Virol 155:1923–1931

    Article  CAS  PubMed  Google Scholar 

  21. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM (2000) A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 44:920–928

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Paolucci S, Baldanti F, Zavattoni M, Gerna G (2004) Novel recombinant phenotypic assay for clonal analysis of reverse transcriptase mutations conferring drug resistance to HIV-1 variants. J Antimicrob Chemother 53:766–771

    Article  CAS  PubMed  Google Scholar 

  23. Arts EJ, Hazuda DJ (2012) HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2:a007161

    Article  PubMed Central  PubMed  Google Scholar 

  24. Hazuda DJ (2012) HIV integrase as a target for antiretroviral therapy. Curr Opin HIV AIDS 7:383–389

    Article  CAS  PubMed  Google Scholar 

  25. Zhang YM, Imamichi H, Imamichi T, Lane HC, Falloon J, Vasudevachari MB, Salzman NP (1997) Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 71:6662–6670

    PubMed Central  CAS  PubMed  Google Scholar 

  26. Banke S, Lillemark MR, Gerstoft J, Obel N, Jørgensen LB (2009) Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations. J Virol 83:8916–8924

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Robinson LH, Gale CV, Kleim JP (2002) Inclusion of full length human immunodeficiency virus type 1 (HIV-1) gag sequences in viral recombinants applied to drug susceptibility phenotyping. J Virol Methods 104:147–160

    Article  CAS  PubMed  Google Scholar 

  28. Hertogs K, de Béthune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, Van Den Eynde C, Van Gerwen V, Azijn H, Van Houtte M, Peeters F, Staszewski S, Conant M, Bloor S, Kemp S, Larder B, Pauwels R (1998) A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 42:269–276

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Pérez-Elías MJ, Lanier R, Muñoz V, Garcia-Arata I, Casado JL, Marti-Belda P, Moreno A, Dronda F, Antela A, Marco S, Moreno S (2000) Phenotypic testing predicts virological response in successive protease inhibitor-based regimens. AIDS 14:F95–F101

    Article  PubMed  Google Scholar 

  30. Condra JH (1998) Resistance to HIV protease inhibitors. Haemophilia 4:610–615

    Article  CAS  PubMed  Google Scholar 

  31. Dunne AL, Mitchell FM, Coberly SK, Hellmann NS, Hoy J, Mijch A, Petropoulos CJ, Mills J, Crowe SM (2001) Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs. AIDS 15:1471–1475

    Article  CAS  PubMed  Google Scholar 

  32. Hirsch HH, Drechsler H, Holbro A, Hamy F, Sendi P, Petrovic K, Klimkait T, Battegay M (2005) Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care. Eur J Clin Microbiol Infect Dis 24:733–738

    Article  CAS  PubMed  Google Scholar 

  33. Ring A, Dowsett M (2004) Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11:643–658

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fujian Provincial Center for Disease Control and Prevention, No. 76 Jintai Road, Fuzhou, Fujian Province, 350001, China

    Shouli Wu, Pingping Yan, Yansheng Yan, Lijun Qiu & Meirong Xie

  2. Fujian Province Key Laboratory of Zoonosis Research, No. 76 Jintai Road, Fuzhou, Fujian Province, 350001, China

    Shouli Wu, Pingping Yan, Yansheng Yan, Lijun Qiu & Meirong Xie

  3. School of Public Health, Fujian Medical University, No. 88 Jiaotong Road, Fuzhou, Fujian Province, 350004, China

    Shouli Wu, Pingping Yan & Yansheng Yan

Authors
  1. Shouli Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pingping Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yansheng Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lijun Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Meirong Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yansheng Yan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, S., Yan, P., Yan, Y. et al. A single-loop recombinant pseudotyped-virus-based assay to detect HIV-1 phenotypic resistance. Arch Virol 160, 1385–1395 (2015). https://doi.org/10.1007/s00705-015-2386-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00705-015-2386-2

Keywords

Search

Navigation